Dexorgen Inc.
North Bethesda, MD Doing business as Codex Biosolutions Inc. Research And Development
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 12358 Parklawn Dr #250a, North Bethesda, MD 20852, USA
- Website
- dexorgen.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | -$24,840 |
| FY2025 | -$30 |
| FY2024 | $79,170 |
| FY2023 | $116,370 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Similar vendors
About the company
Dexorgen Inc., operating as Codex Biosolutions Inc., is a minority-owned, small disadvantaged business specializing in advanced biotechnological research and development services. Registered in SAM.gov since 2010 and located in North Bethesda, Maryland, the company focuses on cell line development, genetic engineering, and translational science support for federal agencies. As a corporate entity, Dexorgen Inc. is classified as a for-profit organization with a specific focus on Asian-Pacific American ownership and small business certification.
The company has consistently secured federal contract awards primarily from the National Institutes of Health (NIH) agencies, including the National Center for Advancing Translational Sciences (NCATS), National Institute of Allergy and Infectious Diseases (NIAID), and the National Institute on Drug Abuse. Their contract work predominantly involves specialized scientific services such as generating stable cell lines, constructing cell lines expressing specific protein variants, and developing research tools for various scientific investigations. Recent contract awards have focused on COVID-19 research, including creating pseudoparticles for viral entry inhibition assays, constructing cell lines expressing SARS-CoV-2 spike protein variants, and developing cell lines for HTLV envelope protein production. Their contracts range in value from approximately $11,250 to $35,025, typically structured as firm fixed-price purchase orders with completion dates ranging from several months to a year. None of their identified contracts have specific set-aside designations, and they have worked on projects involving brain organoid generation, calcium channel cell line development, and genetic research supporting translational medicine.
Quick answers
Is Dexorgen Inc. registered in SAM.gov?
Yes. Dexorgen Inc.'s SAM.gov registration is active through March 16, 2027.
What is Dexorgen Inc.'s CAGE code?
Dexorgen Inc.'s CAGE code is 62JZ3, and its Unique Entity ID (UEI) is ZNUMJ4FKRC19.
How much has Dexorgen Inc. received in federal contracts?
Federal contracts obligated $170,670 to Dexorgen Inc. in fiscal years 2023 through 2027.
What is Dexorgen Inc.'s most recent federal award?
Dexorgen Inc.'s most recent federal contract award is Develop and optimize antagonists assays in ACVR1-WT, ACVR1-R206H, ACVR1-T283I and ACVR1-R206H-T283I cells (75N95C25P00106), from National Center for Advancing Translational Sciences (NIH), on September 18, 2025.
On GovTribe
See Dexorgen Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors